Vistagen Therapeutics (VTGN) Short Interest Ratio & Short Volume → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free VTGN Stock Alerts $4.72 -0.11 (-2.28%) (As of 04/24/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Vistagen Therapeutics Short Interest DataCurrent Short Volume1,280,000 sharesPrevious Short Volume1,330,000 sharesChange Vs. Previous Month-3.76%Dollar Volume Sold Short$6.76 millionShort Interest Ratio / Days to Cover4.4Last Record DateMarch 31, 2024Outstanding Shares27,020,000 sharesFloat Size24,290,000 sharesShort Percent of Float5.27%Today's Trading Volume147,550 sharesAverage Trading Volume279,852 sharesToday's Volume Vs. Average53% Short Selling Vistagen Therapeutics ? Sign up to receive the latest short interest report for Vistagen Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatVTGN Short Interest Over TimeVTGN Days to Cover Over TimeVTGN Percentage of Float Shorted Over Time Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> Vistagen Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/20241,280,000 shares $6.76 million -3.8%5.3%4.4 $5.28 3/15/20241,330,000 shares $5.39 million -8.9%5.5%4.7 $4.05 2/29/20241,460,000 shares $7.46 million -15.1%6.0%3.6 $5.11 2/15/20241,720,000 shares $9.32 million +27.4%7.1%4.1 $5.42 1/31/20241,350,000 shares $6.45 million +16.4%5.6%2.6 $4.78 1/15/20241,160,000 shares $6.32 million -28.8%4.8%2.1 $5.45 Get the Latest News and Ratings for VTGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Vistagen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/20231,630,000 shares $8.38 million +37.0%6.7%2.7 $5.14 12/15/20231,190,000 shares $5.93 million -4.8%4.9%1.8 $4.98 11/30/20231,250,000 shares $4.49 million -21.4%5.1%2.1 $3.59 11/15/20231,590,000 shares $5.23 million +2.6%6.4%2.7 $3.29 10/31/20231,550,000 shares $4.93 million +14.8%7.0%1.4 $3.18 10/15/20231,350,000 shares $4.64 million +61.6%6.1%0.7 $3.44 9/30/2023835,300 shares $4.38 million +16.8%3.5%0.4 $5.24 9/15/2023715,100 shares $4.25 million -31.9%7.7%0.4 $5.95 8/31/20231,050,000 shares $5.60 million -18.0%11.3%0.6 $5.33 8/15/20231,280,000 shares $8.04 million +132.2%13.8%0.7 $6.28 7/31/2023551,300 shares $1.00 million +18.1%7.0%0.4 $1.82 7/15/2023467,000 shares $826,590.00 +36.3%6.0%2.3 $1.77 6/30/2023342,600 shares $640,662.00 -50.2%4.4%1.7 $1.87 6/15/2023687,500 shares $1.43 million +72.2%9.5%3.2 $2.08 5/31/2023399,200 shares $1.70 million -96.8%N/A2.3 $4.26 5/15/202312,450,000 shares $1.75 million -12.0%N/A3.6 $0.14 4/30/202314,150,000 shares $1.98 million -10.6%N/A3 $0.14 4/15/202315,820,000 shares $2.19 million +25.0%N/A2.9 $0.14 3/31/202312,660,000 shares $1.58 million +47.7%N/A2.1 $0.12 3/15/20238,570,000 shares $1.31 million +17.4%N/A1.2 $0.15 2/28/20237,300,000 shares $1.28 million -14.9%N/A1 $0.18 2/15/20238,580,000 shares $1.70 million -15.8%N/A1.1 $0.20 1/31/202310,190,000 shares $2.64 million -17.8%N/A1.5 $0.26 1/15/202312,400,000 shares $1.98 million -19.7%N/A2.1 $0.16 12/30/202215,440,000 shares $1.59 million +36.9%N/A2.5 $0.10 12/15/202211,280,000 shares $1.27 million +24.2%N/A2.1 $0.11 11/30/20229,080,000 shares $1.25 million -1.2%N/A1.7 $0.14 11/15/20229,190,000 shares $1.46 million +13.7%N/A1.5 $0.16 10/31/20228,080,000 shares $1.07 million +26.5%4.6%0.9 $0.13 10/15/20226,390,000 shares $713,124.00 +12.9%3.6%0.5 $0.11 9/30/20225,660,000 shares $860,886.00 +18.4%3.2%0.4 $0.15 9/15/20224,780,000 shares $916,326.00 -12.8%2.7%0.3 $0.19 8/31/20225,480,000 shares $1.01 million -13.3%3.1%0.4 $0.18 8/15/20226,320,000 shares $995,400.00 -30.1%4.1%0.5 $0.16Pentagon contract could send this $2 AI stock soaring (Ad)Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> VTGN Short Interest - Frequently Asked Questions What is Vistagen Therapeutics' current short interest? Short interest is the volume of Vistagen Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 31st, traders have sold 1,280,000 shares of VTGN short. 5.27% of Vistagen Therapeutics' shares are currently sold short. Learn More on Vistagen Therapeutics' current short interest. What is a good short interest ratio for Vistagen Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VTGN shares currently have a short interest ratio of 4.0. Learn More on Vistagen Therapeutics's short interest ratio. Which institutional investors are shorting Vistagen Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Vistagen Therapeutics: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Vistagen Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.27% of Vistagen Therapeutics' floating shares are currently sold short. Is Vistagen Therapeutics' short interest increasing or decreasing? Vistagen Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 1,280,000 shares, a decrease of 3.8% from the previous total of 1,330,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Vistagen Therapeutics' float size? Vistagen Therapeutics currently has issued a total of 27,020,000 shares. Some of Vistagen Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Vistagen Therapeutics currently has a public float of 24,290,000 shares. How does Vistagen Therapeutics' short interest compare to its competitors? 5.27% of Vistagen Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Vistagen Therapeutics: CytomX Therapeutics, Inc. (4.90%), Eliem Therapeutics, Inc. (0.07%), Karyopharm Therapeutics Inc. (19.94%), Nuvectis Pharma, Inc. (12.12%), Repare Therapeutics Inc. (2.39%), FibroGen, Inc. (5.65%), OptiNose, Inc. (2.76%), Citius Pharmaceuticals, Inc. (7.81%), Coya Therapeutics, Inc. (1.53%), Sagimet Biosciences Inc. (19.41%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Vistagen Therapeutics stock? Short selling VTGN is an investing strategy that aims to generate trading profit from Vistagen Therapeutics as its price is falling. VTGN shares are trading up $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Vistagen Therapeutics? A short squeeze for Vistagen Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VTGN, which in turn drives the price of the stock up even further. How often is Vistagen Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VTGN, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: CytomX Therapeutics Short Interest Eliem Therapeutics Short Interest Karyopharm Therapeutics Short Interest Nuvectis Pharma Short Interest Repare Therapeutics Short Interest FibroGen Short Interest OptiNose Short Interest Citius Pharmaceuticals Short Interest Coya Therapeutics Short Interest Sagimet Biosciences Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VTGN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe Greatest Bull Market in Crypto History…Weiss RatingsUrgent Nvidia WarningAltimetry